11549 RESULTS
COMMENT This selective panel of 48 CSF protein study, found from deep discovery-based proteomics in AD patients defined by Aβ42, tTau, and pTau181 difference compared to control individuals, gives novel insights on biological, cellular process of current biomarke
COMMENT Some of us are old enough to remember the 1986 useful proteomic discovery of a 14-3-3 spot on a two-dimensional gel, which proved to be of diagnostic value for Creutzfeldt-Jakob disease (Harrington et al., 1986). Since then, proteomic approaches on bioflu
COMMENT This paper continues a series of home runs by this group. By organizing measurements of diagnostically informative proteins into larger groups defined through functional or physical relationships, it give us blind men a more global appreciation of the pro
COMMENT This paper follows close on the heels of several proteomic studies that interrogated biofluids for predictive AD biomarkers, including groundbreaking work from the Emory group and collaborators themselves. Whereas in their recent Johnson et al. Nat Neuros
COMMENT This is such an interesting article! It is known that neurodegeneration-related proteins, including Aβ, tau, α-synuclein, and TDP-43, have some prion-like characteristics in vitro and in some in vivo models, although they appear less infective and less ag
COMMENT These findings are intriguing, although there are some methodological limitations which mean that interpretation is challenging. First, the authors did not directly assess cerebral amyloid angiopathy (CAA) as an exposure, but instead used recurrent ICH as
COMMENT In this intriguing retrospective analysis of two large, independent databases, Zhao and colleagues report that the risk of spontaneous intracerebral hemorrhage (ICH) was significantly increased in recipients of red-blood-cell transfusions from donors who
COMMENT A key advantage of large-scale proteomic analysis is the unbiased examination of protein changes in diverse biological processes beyond well-studied biological pathways and pathological changes in disease conditions. Emerging evidence demonstrates that co
COMMENT This exciting piece of technical work makes use of state-of-the art analytical technologies including fluorescence-activated SEC and mass spectrometry-based proteomics. The recent developments within proteomics and masspec with respect to sensitivity and
COMMENT I agree with the previous comments. Also, a new paper in Nature describes the discovery of
COMMENT Merrill et al. developed a method to detect and characterize cerebrospinal fluid (CSF) lipoproteins by doping in small amounts of fluorescent lipids for enhanced detection and using tandem size exclusion columns to separate a large range of particle sizes
COMMENT Genome association studies have unequivocally linked genetic risks of late-onset Alzheimer's disease with the dysregulation of immune cells, particularly microglia. Interestingly, a number of protective alleles with selective expression in microglia
COMMENT Tsai et al. provide further biological support for PLCG2 as an important Alzheimer’s disease modifying microglial gene by investigating the impact of a novel loss-of-function PLCG2 variant (M28L) in AD mouse models. Previous work has focused on the P522R
COMMENT While mutations in PLCG2 have been extensively linked to late-onset AD risk in humans, little is currently known about the in vivo functions of PLCG2 in neurobiology or AD disease pathoetiology. Findings from this study help to bridge this gap in knowledg
COMMENT Lipoproteins are circulating particles whose primary function is to carry hydrophobic lipids in aqueous environment. Recent evidence has unveiled the intricate nature of lipoproteins. In particular, several groups found that the high-density lipoproteins
